The curious case of 'Luminous' ranibizumab in India
This article was originally published in Scrip
Executive Summary
Novartis has moved court to block India's Intas Pharmaceuticals from manufacturing and selling its version of ranibizumab under the Lumina trademark, which the Swiss multinational appears to suggest rides on its well-documented "Luminous" study.